ENTX Entera Bio Ltd.: institutional ownership and insider trading
29 funds reported holding $19.1M of Entera Bio Ltd. in their latest 13F filings; in Q2 2026 funds net bought $5.07M, with 7 new positions and 6 funds selling out; over the last 12 months insiders bought $141K and sold $0 on the open market; over its last four quarters it reported revenue of $0 and net income of −$17.0M.
ENTX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$7.31M, EPS 0.14
- Quarter ended Mar 31, 2026: revenue $0, net income −$3.51M, EPS 0.07
- Quarter ended Dec 31, 2025: revenue $0, net income −$3.02M, EPS 0.06
- Quarter ended Sep 30, 2025: revenue $0, net income −$3.20M, EPS 0.07
Famous investors holding ENTX
- Renaissance Technologies (Renaissance Technologies): $653K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $86.6K, 0.0% of the portfolio
Largest institutional holders of ENTX
- Knoll Capital Management, LLC — $10.4M
- BVF INC/IL — $4.29M
- Siren, L.L.C. — $1.30M
- RENAISSANCE TECHNOLOGIES LLC — $653K
- Parkman Healthcare Partners LLC — $486K
- PNC FINANCIAL SERVICES GROUP, INC. (PNC) — $483K
- Seven Fleet Capital Management LP — $339K
- SIGNATURE ESTATE & INVESTMENT ADVISORS LLC — $138K
- HighTower Advisors, LLC — $133K
- HRT FINANCIAL LP — $128K
Recent ENTX insider trades
- Mar 9, 2026: Germano Geno J bought 20,000 shares ($26.0K)
- Mar 5, 2026: Ellis Sean bought 10,000 shares ($12.3K)
- Feb 12, 2026: Rubin Steven D bought 5,000 shares ($7.45K)
- Feb 10, 2026: Taitel Haya bought 7,500 shares ($11.1K)
5%+ owners
- BVF PARTNERS L P/IL: 10.0% (Schedule 13D, filed Aug 4, 2026)
- TCG Crossover GP III, LLC: 7.1% (Schedule 13G, filed Aug 4, 2026)
- Vivo Opportunity, LLC: 6.9% (Schedule 13G, filed Aug 4, 2026)